Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
414 studies found for:    T-cell therapy AND lymphoma | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas
Conditions: CD19+ Diffuse Large B-cell Lymphomas;   Follicular Lymphomas;   Mantle Cell Lymphomas
Intervention: Drug: Pembrolizumab
2 Recruiting Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies
Conditions: B-Cell Chronic Lymphocytic Leukemia;   Non-Hodgkin's Lymphoma
Intervention: Drug: T-cell therapy + Rituximab + IL-2
3 Recruiting CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy
Conditions: Leukemia;   Lymphoma
Intervention: Biological: CD19-directed CAR-T cells
4 Recruiting Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Conditions: Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Lymphoma
Intervention: Combination Product: Drugs and Anti-CD19-CAR transduced T cells
5 Not yet recruiting Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma
Condition: Lymphoma
Intervention: Biological: The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)
6 Recruiting Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Conditions: Chronic Lymphocytic Leukemia;   Acute Lymphocytic Leukemia;   Lymphoma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Anti-CD19-CAR transduced T cells
7 Recruiting A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)
Conditions: Refractory Diffuse Large B Cell Lymphoma;   Refractory Primary Mediastinal B Cell Lymphoma;   Refractory Transformed Follicular Lymphoma;   Relapsed/Refractory Transplant Ineligible Diffuse Large B Cell Lymphoma;   Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma;   Relapsed/Refractory Transplant Ineligible Transformed Follicular Lymphoma
Intervention: Biological: KTE-C19
8 Recruiting Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
Conditions: Leukemia, B-Cell;   Lymphoma, B-Cell
Intervention: Biological: CD19CART
9 Recruiting A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Refractory Diffuse Large B Cell Lymphoma
Interventions: Biological: KTE-C19;   Drug: atezolizumab (anti-PD-L1)
10 Not yet recruiting A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
Conditions: B Cell Leukemia;   B Cell Lymphoma
Intervention: Biological: UCART019
11 Recruiting Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Breast Carcinoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Mantle Cell Lymphoma;   Recurrent Non-Small Cell Lung Carcinoma;   Refractory Chronic Lymphocytic Leukemia;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: ROR1 CAR-specific Autologous T-Lymphocytes
12 Recruiting Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Intervention: Biological: Third generation CAR-T cells
13 Recruiting T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
Conditions: Lymphoma, Large-Cell, Anaplasitc;   Hodgkin Disease;   Lymphoma, Hodgkins;   Enteropathy-Associated T-Cell Lymphoma;   Lymphoma, Extranodal NK-T-Cell
Interventions: Biological: Anti-CD30-CAR T cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
14 Recruiting Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL)
Conditions: Non-Hodgkin Lymphoma;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma;   Mantle-cell Lymphoma;   Primary Mediastinal B-cell Lymphoma
Interventions: Biological: JCAR017 single-dose schedule;   Biological: JCAR017 2-dose schedule
15 Recruiting Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Conditions: CD19-Positive Neoplastic Cells Present;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma
Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes;   Other: Laboratory Biomarker Analysis
16 Recruiting Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)
Condition: Cutaneous T Cell Lymphoma
Intervention: Drug: dimethylfumarate
17 Recruiting A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
Condition: T Cell Non-Hodgkin Lymphoma
Intervention: Other: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin
18 Recruiting T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
Conditions: Lymphoma, B-Cell;   Lymphoma, Non-hodgkins;   Lymphoma, Hodgkins;   Leukemia, B-cell
Interventions: Biological: Anti-CD19-CAR T cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
19 Recruiting CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphocytic Leukemia
Condition: Acute Lymphoblastic Leukemia
Intervention: Genetic: Second generation CAR-T cells
20 Recruiting Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Minimal Residual Disease
Interventions: Biological: Chimeric Antigen Receptor T-Cell Therapy;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.